shows the entry criteria relevant to renal function in twenty recent antihypertensive trials identified as above.
Although it is reasonable to exclude severe renal dysfunction in trials of agents for which this is a contraindication, it is clear that many trials unnecessarily exclude patients with renal dysfunction and others display baseline data showing that renal function was generally good. Probably, therefore, these trials have overestimated the renal tolerability of antihypertensive agents in the general population.
ATHEROSCLEROTIC RENOVASCULAR DISEASE AND RENAL FAILURE IN HYPERTENSIVE PATIENTS
Renal artery stenosis has been recognized as a treatable cause of hypertension since the elegant experiments of Goldblatt24. Much of the research effort has focused on patients with radiologically defined renal artery stenosis, including specific causes of the condition such as fibromuscular dysplasia, and a high cure rate has been achieved with revascularization in these patients25. Initially, renal atherosclerotic disease was thought to be uncommon and a rare cause of end-stage renal failure. However, a study in 1989 showed that 6% of patients entering a dialysis programme, and 14% of those over the age of 50 years, had atherosclerotic renovascular disease as the cause of their renal failure26. Lately The coexistence of renal artery stenosis and peripheral vascular disease therefore seems common. However, the interpretation of many studies has been hampered by limitations in the analysis of their data. The most persuasive study from a large patient population is that by Harding et al. 34 who found renal artery narrowing in 30% of 1235 evaluable patients undergoing diagnostic cardiac catheterization. The degree of renal artery stenosis was described as insignificant in 15% of the overall population, significant but unilateral in l 1% and significant bilateral in 4%. The clinical parameters most predictive of the presence of renal artery stenosis were advanced age, congestive cardiac failure and peripheral vascular disease. Also, the prevalence of renal artery stenosis increased in parallel with the number of diseased coronary vessels (9%, 12%, 23% and 41% for disease in 0, 1, 2 or 3 coronary vessels, respectively). Overall, in this study, only 15% of patients with significant renal artery stenosis were free from coronary or peripheral artery disease.
Another group35 looked for renal artery stenosis in 297 patients who had died of myocardial infarction. They found atherosclerotic renal artery stenosis in 12%, again most commonly in older patients prevalence 0% in patients who died below age 50, 4 in patients who died between 50 and 59, and 18% in patients who died at age 80 years or more. The relation between presence of renal artery stenosis and comorbid diseases commonly observed in hypertensive patients is shown in Figure 2 . The prevalence of renal artery stenosis was about six times higher in patients whose medical records indicated hypertension than in their normotensive counterparts. Renal artery stenosis was also associated with a history of renal insufficiency (eleven fold higher than in those who had normal creatinine levels) and proteinuria (eight fold higher than in those with no history of proteinuria).
These studies indicate that patients with atherosclerotic disease or renal impairment have a high prevalence of renovascular disease, and that it commonly goes unrecognized. The importance of atherosclerotic renal artery stenosis is underlined by its effect on prognosis: the twoyear mortality among patients with end-stage rena failure due to renal artery stenosis is about 50%27. To put tis All had been identified as lkely to benefit from treatment with ACE inhibitors; however, renovascular disease was found in 34% of the population (Figure 3 ) even though patients with severely impaired renal function (serum creatinine > 300 ymol/L) had been excluded.
RENAL ARTERY STENOSIS AND THE

RENIN-ANGIOTENSIN SYSTEM
The association between renovascular disease and coronary or peripheral vascular disease is not surprising since the kidneys lie between these two vascular territories. The principal issue raised by the epidemiological studies cited in the previous section is that many patients with occult renovascular disease are likely to be receiving drug-based treatment for hypertension or heart failure in the community. Inevitably, treatments for these patients will be prescribed without reference to the state of their kidneys, so there is a risk of renal dysfunction as a sideeffect of treatment.
Drugs that modulate the activity of the renin-angiotensin system, such as ACE inhibitors, are particularly associated with the development of renal dysfunction in patients with renal artery stenosis. So let us explore the physiological role of angiotensin II in maintaining renal haemodynamics, and The long-term effects of ACE inhibition on renal by maintenance of intraglomerular pressure function are unclear. Figure 4 shows a renal angiogram (reviewed elsewhere4&). This is achieved in part by the formation of angiotensin II, which contracts the efferent arteriole to the glomerulus in response to a fall in pressure within the afferent arteriole, via an action on angiotensin (AT) receptors. Restriction of blood-flow out of the glomerulus helps to maintain glomerular pressure and hence renal function. In the presence of renal artery stenosis, blood-flow into the glomerulus may already be compromised. Angiotensin-II-mediated contraction of the efferent arteriole is therefore vital for the maintenance of glomerular pressure in this setting.
It follows that the ability to maintain intraglomerular pressure may be suppressed by the action of agents that inhibit the production of angiotensin II or the activation of the angiotensin AT1 receptor. Therefore, both ACE inhibitors and angiotensin receptor antagonists can be expected to cause a sudden and dramatic reduction in glomerular filtration in susceptible patients, although renal blood-flow itself may not be greatly affected. When most of the functioning renal tissue is supplied by an artery with severe narrowing, inhibition of the vasoconstrictor effect of angiotensin II in the efferent arteriole will worsen renal function. However, this phenomenon does provide a useful diagnostic marker for the presence of renal artery stenosis. showing renal artery narrowing. A diagnosis of renal vascular disease had not been strongly considered since the patient had been on an ACE inhibitor for more than five years and renal function had only recently changed. The likelihood is that atherosclerosis of the renal artery had progressed gradually, to a critical point where the action of the ACE inhibitor in the kidney became clinically harmful.
In view of the progressive nature of renal atherosclerosis, deterioration of renal function in a patient on a long-term ACE inhibitor must be considered as possibly being caused by the ACE inhibitor.
There is a common fallacy that in unilateral atherosclerotic renal artery stenosis ACE inhibitors will have little effect on renal function. This presumes that renal function is preserved in the contralateral kidney with a 'normal' renal artery. Measurement of single-kidney glomerular filtration rates, however, commonly reveals a severe decrement in the function of these kidneys48. The change in renal function with an ACE inhibitor in a patient with unilateral atherosclerotic renal artery stenosis will thus depend on what proportion of renal function comes from the kidney with the atherosclerotic renal artery stenosis. In some cases this may be most of the renal function48.
WHAT ARE THE IMPLICATIONS OF RENAL ARTERY STENOSIS FOR ANTIHYPERTENSIVE THERAPY?
To arrive at a treatment decision for a hypertensive patient, four important observations must be considered: * Hypertensive patients are a heterogeneous group, and therapy must be tailored as far as possible to the needs of the individual patient * Atherosclerotic renal artery stenosis is a common and occult manifestation of vascular disease in the elderly hypertensive population * Renal artery stenosis may be present, but undetected, in a substantial minority of these patients * ACE inhibitors are likely to have an adverse effect on renal function if haemodynamically significant renal artery stenosis is present, either unilateral or bilateral.
Renal artery stenosis most commonly arises as a comorbid condition with peripheral vascular disease. With a 30-50% prevalence of renal artery stenosis in patients with severe peripheral arterial disease, such patients are at high risk of adverse effects from these agents. Important hypertension and heart failure trials have not included members of this patient group.
The high prevalence of renal artery stenosis in patients with vascular disease points to the need for caution in the use of ACE inhibitors when coronary or especially peripheral atherosclerotic disease is present. Although we might expect benefit from ACE inhibitors in heart failure, there are no data from patients with concomitant renal impairment. For patients who do not need to receive an ACE inhibitor, centrally acting agents or antihypertensive agents with vasodilator effects (including calcium channel blockers, aI-adrenoreceptor antagonists or direct vasodilators) provide alternatives that are unlikely to impair renal function.
